Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

ClinicalTrials.gov ID: NCT01262651

Public ClinicalTrials.gov record NCT01262651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy

Study identification

NCT ID: NCT01262651
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: GW Pharmaceuticals Ltd; Industry
Enrollment: 397 participants

Conditions and interventions

Conditions

Interventions

Nabiximols Drug
Placebo (GA-0034) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 24, 2010
Primary completion: Jul 1, 2015
Completion: Jul 1, 2015
Last update posted: Apr 22, 2018

2010 – 2015

United States locations

U.S. sites: 25
U.S. states: 12
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85027	—
Not listed	Phoenix	Arizona	85028	—
Not listed	El Cajon	California	92020	—
Not listed	Gilroy	California	95020	—
Not listed	Brandon	Florida	33511	—
Not listed	Daytona Beach	Florida	32117	—
Not listed	Holiday	Florida	34691	—
Not listed	Jacksonville	Florida	32257	—
Not listed	Lynn Haven	Florida	32444	—
Not listed	Stuart	Florida	34994	—
Not listed	Winter Park	Florida	32789	—
Not listed	Newnan	Georgia	30265	—
Not listed	Stockbridge	Georgia	30281	—
Not listed	Shreveport	Louisiana	71105	—
Not listed	Saint Louis Park	Minnesota	55426	—
Not listed	Kansas City	Missouri	64132	—
Not listed	Berlin	New Jersey	08009	—
Not listed	Hendersonville	North Carolina	28739	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Philadelphia	Pennsylvania	19146	—
Not listed	Houston	Texas	77024	—
Not listed	Houston	Texas	77089	—
Not listed	Laredo	Texas	78041	—
Not listed	Salt Lake City	Utah	84112	—
Not listed	Salt Lake City	Utah	84124	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01262651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 22, 2018 · Synced Jun 26, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01262651 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →